Genetic evidence supporting a causal role of Janus kinase 2 in prostate cancer: a Mendelian randomization study

References

• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0.
   PubMed Web of Science ®Google Scholar
• Chen X, Kong J, Diao X, et al. Depression, and prostate cancer risk: a Mendelian randomization study. Cancer Med. 2020;9(23):9160–9167. doi: 10.1002/cam4.3493.
   PubMed Web of Science ®Google Scholar
• Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. doi: 10.1016/j.eururo.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Guan X, Polesso F, Wang C, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606(7915):791–796. doi: 10.1038/s41586-022-04522-6.
   PubMed Web of Science ®Google Scholar
• Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70(1):479–499. doi: 10.1146/annurev-med-051517-011947.
   PubMedGoogle Scholar
• Sebesta EM, Anderson CB. The surgical management of prostate cancer. Semin Oncol. 2017;44(5):347–357. doi: 10.1053/j.seminoncol.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res. 2017;23(22):6764–6770. doi: 10.1158/1078-0432.CCR-17-0019.
   PubMed Web of Science ®Google Scholar
• Hubbard SR. Mechanistic insights into regulation of JAK2 tyrosine kinase. Front Endocrinol. 2017;8:361. doi: 10.3389/fendo.2017.00361.
   PubMed Web of Science ®Google Scholar
• Roskoski RJ. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784–803. doi: 10.1016/j.phrs.2016.07.038.
   PubMed Web of Science ®Google Scholar
• He S, Shi J, Mao J, et al. The expression of miR-375 in prostate cancer: a study based on GEO, TCGA data and bioinformatics analysis. Pathol Res Pract. 2019;215(6):152375. doi: 10.1016/j.prp.2019.03.004.
   PubMed Web of Science ®Google Scholar
• Li H, Ahonen TJ, Alanen K, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004;64(14):4774–4782. doi: 10.1158/0008-5472.CAN-03-3499.
   PubMed Web of Science ®Google Scholar
• Beinhoff P, Sabharwal L, Udhane V, et al. Second-generation Jak2 inhibitors for advanced prostate cancer: are we ready for clinical development? Cancers. 2021;13(20):5204. doi: 10.3390/cancers13205204.
   PubMed Web of Science ®Google Scholar
• Udhane V, Maranto C, Hoang DT, et al. Enzalutamide-induced feed-forward signaling loop promotes therapy-resistant prostate cancer growth providing an exploitable molecular target for Jak2 inhibitors. Mol Cancer Ther. 2020;19(1):231–246. doi: 10.1158/1535-7163.MCT-19-0508.
   PubMed Web of Science ®Google Scholar
• Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019;10(4):486–496. doi: 10.1002/jrsm.1346.
   PubMed Web of Science ®Google Scholar
• Birney E. Mendelian randomization. Cold Spring Harb Perspect Med. 2022;12(4):a041302. doi: 10.1101/cshperspect.a041302.
   PubMed Web of Science ®Google Scholar
• Qian X, Xu D, Liu H, et al. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the alpha-adrenergic receptor antagonist. Aging Male. 2017;20(4):250–256. doi: 10.1080/13685538.2017.1358261.
   PubMed Web of Science ®Google Scholar
• Spisak S, Tisza V, Nuzzo PV, et al. A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nat Commun. 2023;14(1):5118. doi: 10.1038/s41467-023-40616-z.
   PubMed Web of Science ®Google Scholar
• Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52(10):1122–1131. doi: 10.1038/s41588-020-0682-6.
   PubMed Web of Science ®Google Scholar
• Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–79. doi: 10.1038/s41586-018-0175-2.
   PubMed Web of Science ®Google Scholar
• Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597–608. doi: 10.1002/gepi.21998.
   PubMed Web of Science ®Google Scholar
• Wang S, Kang H. Weak-instrument robust tests in two-sample summary-data Mendelian randomization. Biometrics. 2022;78(4):1699–1713. doi: 10.1111/biom.13524.
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization studies with weak instruments. Stat Med. 2011;30(11):1312–1323. doi: 10.1002/sim.4197.
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–764. doi: 10.1093/ije/dyr036.
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–389. doi: 10.1007/s10654-017-0255-x.
   PubMed Web of Science ®Google Scholar
• Kong P, Zhang L, Zhang Z, et al. Emerging proteins in CRPC: functional roles and clinical implications. Front Oncol. 2022;12:873876. doi: 10.3389/fonc.2022.873876.
   PubMed Web of Science ®Google Scholar
• Bahcivan A, Gamsizkan M, Kantarcioglu CS, et al. KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature. Aging Male. 2020;23(5):1627–1641. doi: 10.1080/13685538.2021.1901274.
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang X, Basourakos SP, et al. Enzalutamide-resistant progression of castration-resistant prostate cancer is driven via the JAK2/STAT1-dependent pathway. Front Mol Biosci. 2021;8:652443. doi: 10.3389/fmolb.2021.652443.
   PubMed Web of Science ®Google Scholar
• Guo JH, Zhou J, Zhao Y, et al. Normal peripheral prostate stromal cells stimulate prostate cancer development: roles of the c-kit signal. Am J Transl Res. 2015;7(3):502–512.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao Y, Fang J, et al. SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget. 2017;8(32):53518–53530. doi: 10.18632/oncotarget.18591.
   PubMedGoogle Scholar
• Sun Z, Yin S, Zhao C, et al. Inhibition of PD-L1-mediated tumor-promoting signaling is involved in the anti-cancer activity of beta-tocotrienol. Biochem Biophys Res Commun. 2022;617(Pt 2):33–40. doi: 10.1016/j.bbrc.2022.05.082.
   PubMedGoogle Scholar
• Li X, Yang T, Hu M, et al. Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors. Bioorg Chem. 2022;121:105669. doi: 10.1016/j.bioorg.2022.105669.
   PubMed Web of Science ®Google Scholar
• Fu X, Wang D, Shu T, et al. LncRNA NR2F2-AS1 positively regulates CDK4 to promote cancer cell proliferation in prostate carcinoma. Aging Male. 2020;23(5):1073–1079. doi: 10.1080/13685538.2019.1670157.
   PubMed Web of Science ®Google Scholar
• Agarwal C, Tyagi A, Kaur M, et al. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis. 2007;28(7):1463–1470. doi: 10.1093/carcin/bgm042.
   PubMed Web of Science ®Google Scholar
• Levy DE, Darnell JJ. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–662. doi: 10.1038/nrm909.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15(2):79–80. doi: 10.1016/j.ccr.2009.01.009.
   PubMed Web of Science ®Google Scholar
• Abdulghani J, Allen JE, Dicker DT, et al. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLOS One. 2013;8(9):e75414. doi: 10.1371/journal.pone.0075414.
   PubMed Web of Science ®Google Scholar
• Teng Y, Ghoshal P, Ngoka L, et al. Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility. Carcinogenesis. 2013;34(9):1994–1999. doi: 10.1093/carcin/bgt167.
   PubMed Web of Science ®Google Scholar
• Suter MA, Tan NY, Thiam CH, et al. cGAS-STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells. Sci Rep. 2021;11(1):7243. doi: 10.1038/s41598-021-86644-x.
   PubMed Web of Science ®Google Scholar
• Armakolas A, Dimakakos A, Loukogiannaki C, et al. IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors. Mol Med. 2018;24(1):6. doi: 10.1186/s10020-018-0003-z.
   PubMedGoogle Scholar
• Starsichova A, Lincova E, Pernicova Z, et al. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell Signal. 2010;22(11):1734–1744. doi: 10.1016/j.cellsig.2010.06.014.
   PubMed Web of Science ®Google Scholar
• Nasser MI, Han T, Adlat S, et al. Inhibitory effects of schisandrin B on human prostate cancer cells. Oncol Rep. 2019;41(1):677–685.
   PubMed Web of Science ®Google Scholar
• Sreenivasulu K, Nandeesha H, Dorairajan LN, et al. Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia. Aging Male. 2020;23(5):440–446. doi: 10.1080/13685538.2018.1519014.
   PubMed Web of Science ®Google Scholar
• Jung YY, Ko JH, Um JY, et al. LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. J Cell Physiol. 2021;236(7):5253–5264. doi: 10.1002/jcp.30229.
   PubMed Web of Science ®Google Scholar
• Gao M, Li H, Dang F, et al. Induction of proliferative and mutagenic activity by benzo(a)pyrene in PC-3 cells via JAK2/STAT3 pathway. Mutat Res. 2020;821:111720. doi: 10.1016/j.mrfmmm.2020.111720.
   PubMed Web of Science ®Google Scholar
• Dong Y, Lu B, Zhang X, et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis. 2010;31(12):2097–2104. doi: 10.1093/carcin/bgq167.
   PubMed Web of Science ®Google Scholar
• Bao X, Zhu J, Ren C, et al. Beta-elemonic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF-kB signal pathways. Chem Biol Interact. 2021;342:109477. doi: 10.1016/j.cbi.2021.109477.
   PubMed Web of Science ®Google Scholar
• Xu LJ, Ma Q, Zhu J, et al. Combined inhibition of JAK1,2/Stat3PDL1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. Mol Med Rep. 2018;17(6):8111–8120.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Xu X, et al. N6-substituted adenosine analogues, a novel class of JAK2 inhibitors, potently block STAT3 signaling in human cancer cells. Cancer Lett. 2014;354(1):43–57. doi: 10.1016/j.canlet.2014.07.043.
   PubMed Web of Science ®Google Scholar
• Shodeinde AL, Barton BE. Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther. 2012;5:119–125.
   PubMed Web of Science ®Google Scholar
• Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 2012;360(1–2):3–13. doi: 10.1016/j.mce.2011.09.046.
   PubMed Web of Science ®Google Scholar
• Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33(2–3):413–427. doi: 10.1007/s10555-013-9474-0.
   PubMed Web of Science ®Google Scholar
• Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–238. doi: 10.1016/j.pharmthera.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Qian S, Xia J, Liu H, et al. Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. Aging Male. 2018;21(4):231–237. doi: 10.1080/13685538.2018.1424129.
   PubMed Web of Science ®Google Scholar
• Hoang DT, Iczkowski KA, Kilari D, et al. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017;8(2):3724–3745. doi: 10.18632/oncotarget.12554.
   PubMedGoogle Scholar